BIT Capital GmbH acquired a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 94,344 shares of the company's stock, valued at approximately $1,149,000. BIT Capital GmbH owned approximately 0.16% of Cullinan Therapeutics as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its stake in shares of Cullinan Therapeutics by 580.9% during the 4th quarter. JPMorgan Chase & Co. now owns 198,214 shares of the company's stock worth $2,414,000 after purchasing an additional 169,104 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in Cullinan Therapeutics in the fourth quarter valued at about $179,000. KLP Kapitalforvaltning AS purchased a new stake in Cullinan Therapeutics during the 4th quarter valued at about $83,000. American Century Companies Inc. lifted its position in Cullinan Therapeutics by 11.0% during the fourth quarter. American Century Companies Inc. now owns 100,721 shares of the company's stock valued at $1,227,000 after purchasing an additional 10,010 shares during the period. Finally, Intech Investment Management LLC grew its position in Cullinan Therapeutics by 81.7% during the 4th quarter. Intech Investment Management LLC now owns 31,782 shares of the company's stock worth $387,000 after purchasing an additional 14,295 shares during the period. Hedge funds and other institutional investors own 86.31% of the company's stock.
Analyst Ratings Changes
Several research analysts recently weighed in on the company. Morgan Stanley reiterated an "overweight" rating and set a $35.00 price target (down from $38.00) on shares of Cullinan Therapeutics in a research report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Cullinan Therapeutics in a report on Friday, February 28th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Cullinan Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $32.86.
Check Out Our Latest Stock Analysis on CGEM
Insider Activity at Cullinan Therapeutics
In other news, insider Jennifer Michaelson sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $12.51, for a total value of $50,040.00. Following the completion of the sale, the insider now directly owns 95,760 shares of the company's stock, valued at $1,197,957.60. This trade represents a 4.01 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nadim Ahmed sold 12,529 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total transaction of $106,872.37. Following the sale, the chief executive officer now directly owns 430,621 shares in the company, valued at approximately $3,673,197.13. This represents a 2.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,424 shares of company stock worth $198,667 in the last quarter. Company insiders own 6.07% of the company's stock.
Cullinan Therapeutics Price Performance
Shares of NASDAQ:CGEM traded down $0.64 during mid-day trading on Monday, reaching $7.38. 114,332 shares of the company were exchanged, compared to its average volume of 444,357. The firm has a market cap of $431.71 million, a price-to-earnings ratio of -2.61 and a beta of -0.12. The firm's 50-day simple moving average is $9.31 and its 200 day simple moving average is $12.55. Cullinan Therapeutics, Inc. has a 1 year low of $7.30 and a 1 year high of $30.19.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.02. On average, research analysts forecast that Cullinan Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year.
Cullinan Therapeutics Profile
(
Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Recommended Stories

Before you consider Cullinan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.
While Cullinan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.